MiRaDoR: A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population (clinicaltrials.gov) - Sep 25, 2026 - P2 | N=976 | Active, not recruiting | Sponsor: MedSIR | Recruiting ➔ Active, not recruiting
Circulating tumor DNA • Enrollment closed • Minimal residual disease • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • HER-2
|